Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Management reported treating 12 patients since launch, including 5 in Q2 2026, though revenue was recognized for only 4 treatments due to manufacturing variability.
The company achieved its goal of activating 7 qualified treatment centers (QTCs) by year-end, including high-volume sites like Cincinnati Children's and CHOP. Operational complexity is driven by ZEVASKYN's 84-hour shelf life, requiring precise real-time coordination between dermatologists, surgeons, and anesthesiologists. Patient health volatility led to two last-minute biopsy cancellations in Q2, which could not be backfilled due to the extensive pre-scheduling required for surgical slots.
Manufacturing yields are averaging 9 sheets per lot, which is higher than clinical trial averages, though one low-yield batch fell below the 4-sheet revenue recognition threshold. Management is shifting reporting metrics to focus on completed treatments and recognized revenue rather than leading indicators like scheduled biopsies, which have proven unpredictable. The company expects a steady-state cadence of approximately 1 patient per month per QTC once centers move past the initial learning curve.
CMS granted New Technology Add-on Payment (NTAP) status effective October 1, 2026, which management believes will facilitate access for the 10% Medicare patient mix. Abeona is working with the FDA to revise specifications for the Pan-CK identity test after a batch failed a threshold set during BLA review based on limited data. Management believes clinical conviction will reach a 'tipping point' as early treaters share positive real-world outcomes through peer-to-peer dialogue.
The financial strategy targets a sustainable cash-flow-positive model by maintaining a consistent cadence of patient treatments and leveraging a largely fixed manufacturing cost base. One batch was designated 'out of specification' due to a new identity test not used in clinical trials; the patient was treated, but no revenue was recognized. Q2 gross margins were 63%, but management anticipates normalized margins of 85% to 90% as volumes increase and fixed costs are better absorbed.
R&D expenses decreased significantly quarter-over-quarter following a one-time $7 million in-licensing cost for ABO-701 in Q1 2026. The company maintains a cash position of $146.8 million as of June 30, 2026, to support the ongoing commercial rollout. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
